Table 1.
Baseline Demographics
| cSLE Subjects N=41 |
Control Subjects N=22 |
p-value | ||
|---|---|---|---|---|
| Age in years (mean ± SD) Range |
16.4 ± 2.5 (10.3 – 21.8) |
17.7 ± 3.0 (10.5 – 21.7) |
.06 | |
| Gender (N, %) | 30 F (73) | 14 F (64) | ns | |
| Ethnicity (N, %) | ||||
| Hispanic | 28 (68) | 16 (73) | ns | |
| African-American | 5 (12) | 3 (14) | ||
| Asian | 4 (10) | 2 (9) | ||
| Caucasian | 3 (7) | 1 (5) | ||
| Other (mixed race/ethnicity) | 1 (3) | 1 (5) | ||
| Yearly Household Income (N, %) | ||||
| <$25,000 | 18 (44) | 13 (59) | ns | |
| $25,000 – $49,999 | 12 (29) | 4 (18) | ||
| $50,000 – $99,999 | 5 (12) | 2 (9) | ||
| $100,000 – $150,000 | 1 (3) | 0 | ||
| >$150,000 | 5 (12) | 3 (14) | ||
| Disease Duration in Yrs (mean ± SD) (Range) |
3.6 ± 2.4 (0.4 – 12.4) |
N/A | ||
| Neuropsychiatric Issuesa (N, %) | ||||
| Headache | 13 (32) | N/A | ||
| Depression | 2 (5) | |||
| Psychosis | 1 (3) | |||
| Seizures | 1 (3) | |||
| Medicationsa | ||||
| Hydroxychloroquine | 40 (98) | N/A | ||
| Prednisone (N, %) | 25 (61) | |||
| Pred dose (mg/kg/d) (mean, range) | 0.23 (0.03 – 0.7) | |||
| Azathioprine | 5 (12) | |||
| Cyclophosphamide | 1 (2) | |||
| Mycophenolate Mofetil | 14 (34) | |||
| Methotrexate | 3 (7) | |||
| BDI Score (Mean ± SD) (Test Range 0 – 63) |
7.5 ± 6.0 (0 – 23) |
4.4 ± 6.6 (0 – 30) |
.07 | |
| PedsQL Score (Mean ± SD) (Test Range 0 – 100) |
73.3 ± 13.7 (46 – 100) |
88.7 ± 9.3 (62 – 100) |
<.001 | |
| Mean WASI FSIQ (Mean ± SD) (Range) |
96.8 ± 10.3 (70 – 119) |
96.7 ± 11.1 (65 – 116) |
ns | |
a
At time of neuropsychological testing; BDI – Beck Depression Inventory; PedsQL – Pediatric Quality of Life Scale; WASI – Weschler Abbreviated Intelligence Score; FSIQ – Full Scale IQ score